

## Statement of total voting rights and shares forming the company's share capital on October 31<sup>st</sup>, 2024

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris  
ISIN code / Mnemo: FR0013233012/ IVA  
Web site: [www.inventivapharma.com](http://www.inventivapharma.com)

| Date            | Number of Shares Outstanding | Total voting rights, gross <sup>(1)</sup> | Total voting rights, net <sup>(2)</sup> |
|-----------------|------------------------------|---|---|
| 31 October 2024 | 87 077 695                   | 100 059 052                               | 99 939 331                              |

<sup>(1)</sup> The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

<sup>(2)</sup> The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.